You can also listen to this podcast on iono.fm here. ADVERTISEMENT CONTINUE READING BELOW Download the free LiSTN audio app on Google Play, Apple or here.
STEPHEN SAAD: Yes, we had a very good second half, and this financial year we’ve really focused on delivering on our manufacturing contracts. That’s been critical for us.What drove some of our revenue was a change in the model of one of the commodity products that we have – which was heparin. So we will have a very good second half again this year because of having those contracts in place. And they roll out quite substantially from, say, R500 million in this financial year, R3 billion next year, and at least R4 billion the following year. So it’s proving to be a worthwhile investment decision to have invested in that sterile capacity.
They have entrusted Aspen with the manufacture of their insulin. It so happens that they use a similar capability and similar technology as Covid. TINUS DE JAGER: Stephen, the rand’s volatility is still bad – it’s even worse than when you spoke to us six months ago. How is that affecting business?
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TechCentral - 🏆 8. / 71 Read more »
Source: htxtafrica - 🏆 42. / 51 Read more »
Source: Moneyweb - 🏆 5. / 77 Read more »